Saltigo (Langenfeld, Germany), a Lanxess subsidiary, says it has discontinued production at the company’s Redmond, WA, site and that it has abandoned a previously announced plan to produce potent active pharmaceutical ingredients (API) at that site. “We have decided to focus more on launched products or products in Phase 3 clinical trials and the Redmond site was involved in products required during phases 1 and 2. So we have decided not to continue our activities in the US,” Wolfgang Schmitz, CEO of Saltigo, told CW at the CPhI trade...